Overview: Type 2 diabetes mellitus (T2DM) accounts for approximately 90% to 95% of diabetes cases and is challenging to manage, with contributing pathophysiologic abnormalities ranging from predominant insulin resistance with relative insulin deficiency to predominant insulin secretory defect with insulin resistance. The leading cause of death in people with T2DM is cardiovascular disease (CVD), and patients with T2DM are at an increased risk of multiple cardiovascular comorbidities, such as heart failure and stroke. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a class of glucose-lowering medications capable of reducing cardiovascular risk while also helping patients achieve individualized glycemic goals; however, many clinicians remain unaware of both emerging cardiovascular and renal risk reduction data with these agents and recommendations for appropriate use of these agents in clinical practice.
Join our expert faculty as he provides the most up-to-date science regarding GLP-1 RAs. This engaging three-part webinar series focuses on current and emerging agents and evolving clinical guideline recommendations. Learn about currently available agents,their associated cardiovascular and renal benefits, novel formulations in late-stage development, important considerations for individualized patient care, and counseling and education strategies with the ultimate goal of improving care and outcomes in your patients with T2DM.
Provided in this webcast will be a downloadable Point-of-Care Reference Tool. This unique reference will serve as a valuable resource for your practice providing detailed information, at your fingertips, regarding the management of T2DM with GLP-1 RAs, efficacy of available agents, cardiovascular outcome considerations, and other relevant information as decided by the expert faculty. The Point-of-Care Reference Tool will be available as a downloadable pdf and will be optimized for mobile use at the point of care, as well, making it easy to access and share with colleagues.
Don't miss the final live webinar of this three-part webinar series
Thursday, January 16, 2020 at 1:00PM EST
Joshua J. Neumiller, PharmD, CDE, FAADE, FASCP
Vice-Chair & Allen I. White Distinguished Associate Professor of Pharmacotherapy
Department of Pharmacotherapy
College of Pharmacy and Pharmaceutical Sciences
Washington State University
Spokane, WA

Educational Objectives
Discuss current clinical recommendations for GLP-1 RA use in the management of type 2 diabetes mellitus.
Review dosing, administration, and safety considerations for agents within the GLP-1 RA class.
Formulate a comprehensive management plan for a patient with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease.
UAN: 0430-0000-20-001-L01-P
Credits: 1.25 hour (0.125 ceu)
Activity Type: Application
Duration: 75 minutes
Location: From the convenience of your home or business; accessible via both PC and MAC
Fee: There is no fee for this educational activity
Missed part of this program? You may access the first two webinars in the series at powerpak.com
Accreditation Statements
Pharmacy: Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Required Computer Hardware/Software
Operating System: Windows 98 or higher & Macintosh 2.2 or higher
Internet Browser (Mac &/ Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
Peripherals: Computer speakers or headphones
Monitor Screen Resolution: 320 x 480 or higher
Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5
These educational activities are sponsored by Postgraduate Healthcare Education, LLC (PHE) and supported by an educational grant from Novo Nordisk Inc.